FY2017 profit upgrade

FY2017 profit upgrade

19-January-2017 — CSL Limited today upgraded its net profit after tax (NPAT) expectation for FY2017. Following strong sales performance CSL expects to report NPAT of approximately US$800 million for the six months ended 31 December 2016. More.

AFSTYLA® (rFVIII), for Haemophilia A, receives European Commission Approval

09-January-2017 — CSL today announced that the European Commission has granted marketing authorisation for CSL Behring's AFSTYLA® for children and adults with haemophilia A. More.

Other recent news:

05-January-2017 — Momenta and CSL have entered into an exclusive research collaboration and worldwide license agreement to develop and commercialize Fc multimer proteins, including Momenta’s M230, a selective immunomodulator of Fc receptors, which is expected to enter the clinic in 2017. More.
22-December-2016 — CSL Limited (ASX:CSL), parent company of CSL Behring, has recorded another strong performance in corporate responsibility, outlining in its 2015/16 report the top 15 sustainability aspects important to its operations and stakeholders. More.
01-December-2016 — CSL has announced that it has progressed three new therapies into first-in-human studies in Australia. In keeping with the Company's objective to expand its research and development pipeline and pursue a diverse portfolio, all three products are new generation, high-tech medicines based on targeted monoclonal antibody technologies. More.

© 2017 CSL Limited